Symproic (naldemedine) / Shionogi, Collegium Pharma 
Welcome,         Profile    Billing    Logout  
 7 Diseases   5 Trials   5 Trials   247 News 


1234»
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Retrospective data, Review, Journal:  Safety of Naldemedine for Opioid-Induced Constipation - A Systematic Review and Meta-Analysis. (Pubmed Central) -  Dec 19, 2024   
    This analysis confirms naldemedine's overall safety in treating opioid-induced constipation, with manageable gastrointestinal side effects. However, the higher adverse events in cancer patients require further investigation to ensure safe use in this population.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Journal:  Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Children. (Pubmed Central) -  Oct 17, 2024   
    In some patients, grade 2 diarrhea required naldemedine discontinuation, suggesting that it should be used with caution in pediatric patients. Further studies are warranted to determine the optimal naldemedine dose in pediatric patients.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Trial completion date, Trial primary completion date:  Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids (clinicaltrials.gov) -  Oct 15, 2024   
    P1/2,  N=24, Recruiting, 
    Further studies are warranted to determine the optimal naldemedine dose in pediatric patients. Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> Jun 2026
  • ||||||||||  Journal:  Emerging therapies for opioid-induced constipation: what can we expect? (Pubmed Central) -  Oct 11, 2024   
    Other treatment options, including intestinal secretagogues like lubiprostone and linaclotide, selective 5-HT receptor agonists such as prucalopride, and emerging adjunctive therapies like transcutaneous electrical nerve stimulation (TENS) and electroacupuncture were mentioned...Emerging therapies and adjunctive treatments offer promising results but require further validation through rigorous studies. Future research should focus on long-term outcomes, cost-effectiveness, and comparative effectiveness to better address the complex needs of patients with OIC and refine treatment protocols.
  • ||||||||||  Nucynta (tapentadol) / Collegium Pharma, Grunenthal
    The prevalence of tapentadol-induced constipation following cancer pain treatment (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_2498;    
    More than half patients have not revealed constipation during tapentadol treatment, although the prevalence of chronic constipation since before was 34.8% (8/23). We conclude tapentadol should be prescribed for cancer pain treatment because of a high effectivity and better gastrointestinal tolerability profile.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Journal:  Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain. (Pubmed Central) -  Apr 11, 2024   
    The incidence of addition, change, or dose increase was significantly higher in the naldemedine arm than in the magnesium oxide arm of the early prescription group (hazard ratio (95% confidence interval), 1.08 (1.00, 1.17); p=0.0402); the incidence was comparable between the arms of the non-early group. Conclusion These findings may provide valuable insights into real-world clinical treatment patterns and preliminary evidence for the selection of first-line medications to mitigate opioid-induced constipation in Japanese patients with cancer pain.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma, Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin, Relistor (methylnaltrexone bromide) / Ono Pharma, Bausch Health
    Review, Journal:  Opioid-induced Constipation: Old and New Concepts in Diagnosis and Treatment. (Pubmed Central) -  Apr 5, 2024   
    The bowel functional index is the main tool for assessing the severity of OIC and for monitoring the response. The paper discusses the recent literature on the pathophysiology, clinical evaluation, and management of OIC and provides a pragmatic approach for its assessment and treatment.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Enrollment closed, Enrollment change:  Effects of a Peripherally Acting  (clinicaltrials.gov) -  Mar 21, 2024   
    P2/3,  N=74, Active, not recruiting, 
    Larger-scale randomized placebo-controlled studies of PAMORAs in cancer patients would strengthen existing evidence. Recruiting --> Active, not recruiting | N=120 --> 74
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Journal:  Naldemedine-induced opioid withdrawal with restlessness as the predominant symptom in a palliative care setting. (Pubmed Central) -  Jun 23, 2023   
    In the systematic review and meta-analysis, the use of PAMORAs (mainly methylnaltrexone) was safe and associated with a reduced intolerance to enteral feeding but no difference in the time to laxation. Patients receiving palliative care often exhibit psychiatric symptoms such as anxiety and depression, but OWS due to naldemedine should also be considered as a potential cause.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Trial completion date, Trial primary completion date:  Effects of a Peripherally Acting  (clinicaltrials.gov) -  Jun 7, 2023   
    P2/3,  N=120, Recruiting, 
    The patient ultimately required continuous deep sedation for refractory symptoms and died several days later. Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Mar 2024
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Journal:  Opioid withdrawal syndrome developing after long-term administration of naldemedine. (Pubmed Central) -  Mar 24, 2023   
    Naldemedine is effective and safe among cancer patients with poor PS. For patients receiving naldemedine, it is necessary to consider the possibility of OWS regardless of the period of administration in order to maintain patient quality of life.
  • ||||||||||  Journal:  An Update on The Use of Pharmacotherapy for Opioid-Induced Bowel Dysfunction. (Pubmed Central) -  Feb 27, 2023   
    The fundamental reason is the lack of head-to-head clinical trials providing inter- and intragroup comparisons between PAMORAs, laxatives, and secretagogue agents. These investigations must be accompanied by further valid biopharmaceutical and economic evaluations, paving the way for rational clinical judgment in each context.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Journal:  Survey of Prophylactic Administration of Naldemedine for Opioid-induced Constipation (Pubmed Central) -  Feb 2, 2023   
    This study suggests that patients initiated with strong opioid analgesics during hospitalization often presented with poor performance status, and it is important to pay attention to constipation even under NAL prophylaxis. However, the incidence of diarrhea was low, and the safety of NAL prophylaxis was considered to be good.
  • ||||||||||  Journal:  Opioids for pain. (Pubmed Central) -  Dec 22, 2022   
    Not yet recruiting --> Recruiting No abstract available
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Retrospective data, Journal:  Naldemedine versus placebo in opioid-induced constipation: a meta-analysis. (Pubmed Central) -  Dec 16, 2022   
    Naldemedine improves a variety of bowel function parameters while preserving analgesia, confirming its efficacy for patients with OIC. However, head-to-head trials are needed to establish naldemedine as treatment of first choice for laxative-refractory OIC.
  • ||||||||||  Review, Journal:  Management of Opioid-induced Constipation in Older Adults. (Pubmed Central) -  Dec 13, 2022   
    Because of the complex nature of absorption, distribution, metabolism, and excretion in the aging population, all agents used to treat OIC must be evaluated individually and reevaluated as patients continue to age. This review will serve as a guide to managing OIC in older adults.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma, Movantik (naloxegol) / AstraZeneca, RedHill, Kyowa Kirin
    Review, Journal:  The Impact of P-Glycoprotein on Opioid Analgesics: What's the Real Meaning in Pain Management and Palliative Care? (Pubmed Central) -  Nov 27, 2022   
    Peripherally acting mu-opioid receptors antagonists (PAMORAs), such as naloxegol and naldemedine, are substrates of P-gp, which prevent their penetration in the central nervous system. In our review, we explore the interactions between P-gp and opioidergic drugs, with their implications in clinical practice.
  • ||||||||||  lumacaftor (VX-809) / Vertex, Symproic (naldemedine) / Shionogi, Collegium Pharma
    Journal:  Targeting human thymidylate synthase: Ensemble-based virtual screening for drug repositioning and the role of water. (Pubmed Central) -  Oct 19, 2022   
    Further binding free energy calculations based on the Molecular Mechanics Poisson-Boltzmann Surface Area method revealed that Imatinib, Lumacaftor and Naldemedine scored -130.7 ± 28.1, -210.6 ± 29.9 and -238.0 ± 25.4 kJ/mol, respectively, showing good binding affinity for the candidates considered. Overall, the analysis of the molecular dynamics trajectory of the receptor-drug complexes revealed stable structures for Imatinib, Lumacaftor and Naldemedine, for the entire simulation time.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma, Relistor (methylnaltrexone bromide) / Ono Pharma, Bausch Health
    Review, Journal:  Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. (Pubmed Central) -  Sep 20, 2022   
    Moderate-certainty evidence for methylnaltrexone on spontaneous laxations over two weeks suggests subcutaneous methylnaltrexone may improve bowel function in people receiving palliative care, but certainty of evidence for AEs was low. More trials are needed, more evaluation of AEs, outcomes patients rate as important, and in children.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Journal:  A peripheral opioid antagonist for treating urinary retention induced by opioids: A case report. (Pubmed Central) -  Sep 10, 2022   
    Methadone therapy was effective on pain intensity, but bladder dysfunction persisted...Thus, naldemedine 200 mcg was prescribed for relieving urinary retention...In this case report, the effect of the peripheral opioid antagonist was prompt and long-lasting. Future studies of this neglected adverse effect of opioids should be performed to confirm this observation.
  • ||||||||||  Symproic (naldemedine) / Shionogi, Collegium Pharma
    Retrospective data, Journal:  A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients. (Pubmed Central) -  Aug 18, 2022   
    A total of 953 OIC cancer patients were treated with Naldemedine, and the response rate for Spontaneous Bowel Movements (SBM) is 72 % (95 % CI, p = 0.004). The efficacy and safety of naldemedine for thoracic cancer patients in clinical practice were comparable with those of prospective studies, which suggest that naldemedine may be effective and feasible for most thoracic cancer patients.